Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Double-dummy, Parallel-group and Multicenter Study to Investigate Lurasidone in Treatment of Schizophrenia Compared With Risperidone

NCT02002832 is registered in ClinicalTrials.gov with Marubeni Pharmaceuticals (Suzhou) Co., Ltd. as lead sponsor.

NCT NCT02002832
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02002832 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Double-dummy, Parallel-group and Multicenter Study to Investigate Lurasidone in Treatment of Schizophrenia Compared With Risperidone
Lead sponsor
Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2013
Completion date
November 30, 2015
Enrollment
388 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia